Malignant non-Hodgkin's lymphoma (NHL) in patients (pts) enrolled on two large comparative trials (N3300/ACTG 114 and N3492/ACTG 119) of zidovudine (ZDV) and zalcitabine (DDC) (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Malignant non-Hodgkin's lymphoma (NHL) in patients (pts) enrolled on two large comparative trials (N3300/ACTG 114 and N3492/ACTG 119) of zidovudine (ZDV) and zalcitabine (DDC) (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 14:A836 1995. Unique Identifier : AIDSLINE ICDB/95613988
Sprenz V; Platzner A; Remick S; Baruch A; Salgo M; Albany Medical College, Albany, NY

Abstract: NHL is an increasing cause of morbidity and mortality in HIV-infected pts. We reviewed the clinical characteristics of 27 pts (3.6%) enrolled in 2 large comparative trials of ZDV and DDC (N3300 - 635 pts and N3492 - 111 pts) to determine if their was any change in the natural history of this neoplastic complication of HIV infection. Twenty-three (85%) pts had pathological confirmation of NHL. Two pts had clinical criteria and 2 pts had death certificate confirmation judged to be consistent with NHL. Four pts were excluded because of incomplete records. By December 1991, in the N3300 trial, 5.2% of the clinical opportunistic infection and neoplastic endpoints (1.9% pts) were NHL (6 ZDV, 6 DDC). Another 12 pts developed NHL with additional follow-up through February 1993. Three pts (2 ZDV, 1 DDC) had NHL in the N3492 trial, which represented 11.1% of clinical endpoints (2.7% pts). For all 27 pts at time of NHL diagnosis: 100% were male; median age 37 yr (range 24-60); median CD4 lymphocyte count 37/uL (range 3-257); 16 of 21 (76%) cases with histologic confirmation of NHL were high-grade lesions; and median survival was 4 mo (range 0.25-37) with approximately half of all deaths directly related to NHL. The pattern of OIs prior to NHL diagnosis was as follows: 5 pts (19%) had no prior OI; 12 pts (44%) had AIDS-defining OIs (ZDV 4, DDC 8 pts; PCP 8, KS 3, CMV 2, MAI 2 and toxo 1 episodes); and 10 pts (37%) had non-AIDS defining infections (ZDV 5, DDC 5 pts; thrush 8 and 11 other episodes). We conclude the presentation of NHL in HlV-infected pts more than a decade after the onset of the epidemic is unchanged. Further follow-up of the pattern of OIs prior to NHL diagnosis may be important.

Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY/MORTALITY Adult Comparative Study Female Human Lymphoma, AIDS-Related/*EPIDEMIOLOGY/MORTALITY/PATHOLOGY Male Middle Age Survival Rate Zalcitabine/*THERAPEUTIC USE Zidovudine/*THERAPEUTIC USE ABSTRACT CLINICAL TRIAL CONTROLLED CLINICAL TRIAL
951230
M95C3218

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .